TY - JOUR
T1 - Secondary malignancies after hematopoietic stem cell transplantation
AU - Ghelani, Dipak
AU - Saliba, Rima
AU - De Lima, Marcos
PY - 2005/10
Y1 - 2005/10
N2 - Advances in the field of hematopoietic stem cell transplantation have led to an increasing number of cures of malignant and non-malignant diseases with this therapeutic approach. Long-term survivorship may, however, be associated with secondary malignancies, the result of a complex interaction of treatment-, recipient- and immunosuppression-related factors. Furthermore, the increasing use of donors other than human leukocyte antigen-identical siblings is associated with more intense immunosuppression, delayed immune recovery and higher incidence of B-cell post-transplantation lymphoproliferative disorders. Here, we review the incidence and the risk factors associated with these complications of hematopoietic stem cell transplants.
AB - Advances in the field of hematopoietic stem cell transplantation have led to an increasing number of cures of malignant and non-malignant diseases with this therapeutic approach. Long-term survivorship may, however, be associated with secondary malignancies, the result of a complex interaction of treatment-, recipient- and immunosuppression-related factors. Furthermore, the increasing use of donors other than human leukocyte antigen-identical siblings is associated with more intense immunosuppression, delayed immune recovery and higher incidence of B-cell post-transplantation lymphoproliferative disorders. Here, we review the incidence and the risk factors associated with these complications of hematopoietic stem cell transplants.
KW - Secondary malignancy
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=24644491812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24644491812&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2005.03.014
DO - 10.1016/j.critrevonc.2005.03.014
M3 - Review article
C2 - 15979325
AN - SCOPUS:24644491812
SN - 1040-8428
VL - 56
SP - 115
EP - 126
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - 1 SPEC. ISS.
ER -